Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TLPH vs BLRX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TLPH Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 6–2 Matrix Metrics)

TLPH Overall Winner 6-Pillar Tally: TLPH 2 – 2 BLRX (2 Tie) Matrix Metrics: TLPH 6 – 2 BLRX

As of Nov 16, 2026, Talphera, Inc. (TLPH) is the stronger overall head-to-head candidate over BioLineRX Ltd (BLRX) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale). TLPH carries a Unified Composite Score of 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin), whereas BLRX carries 37.1/100 (SELL) at $1.18 (93.5x Forward P/E, -874.3% operating margin).

  • Defensive Composite Rating Caution: Although TLPH compares more favorably head-to-head, both TLPH (37.1/100 SELL) and BLRX (37.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: TLPH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1); meanwhile BLRX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TLPH vs BLRX
TLPH NASDAQ Head-to-Head Winner
Talphera, Inc. Common Stock
Pharmaceutical Preparations
$0.86
-4.98% 1D
Market Cap $53.7M
TTM Revenue $1,000
Forward P/E 1.0x
Beta / 30D Vol 1.11β · 58% Vol
Unified Composite Score
37.1 / 100 SELL
Tech 25.0 Fund 45.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.8%), weak momentum, RSI 26
RSI-14: 26.1 · SMA20: $1.04 · SMA50: $1.10
BLRX NASDAQ
BioLineRX Ltd
Pharmaceutical Preparations
$1.18
-9.23% 1D
Market Cap $6.9M
TTM Revenue $1.4M
Forward P/E 93.5x
Beta / 30D Vol 0.45β · 68% Vol
Unified Composite Score
37.1 / 100 SELL
Tech 25.0 Fund 49.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.0%), weak momentum, RSI 21
RSI-14: 21.0 · SMA20: $1.81 · SMA50: $2.14

6-Pillar Scorecard Institutional Category Breakdown (TLPH 2 – 2 BLRX)

Columns: Metric · TLPH · BLRX
1. Valuation Multiples TLPH
Forward P/E 1.0x 93.5x
Trailing P/E 1.0x 93.5x
PEG Ratio N/M 0.20x
EV / Revenue N/M 5.0x
2. Growth & Scale TLPH
Revenue Growth (YoY) +0.0% -3.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1,000 $1.4M
Market Cap $53.7M $6.9M
3. Profitability & Quality BLRX
Gross Margin N/A 80.0%
Operating Margin -1474700.0% -874.3%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -143.4% -55.3%
4. Balance Sheet & Cash Flow BLRX
Cash Generation (TTM) -$15M EBITDA -$12M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $0.28 Book/Sh · -143.4% ROE $3.00 Book/Sh · -55.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 118.4% (100th %ile) 226.3% (50th %ile)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TLPH (6) vs BLRX (2)
Institutional Metric TLPH BLRX Criterion Row Edge
Market Capitalization
Scale
$53.7M $6.9M Larger Scale TLPH
Trailing P/E Ratio
Valuation
1.0x 93.5x Lower Multiple TLPH
Forward P/E Ratio
Valuation
1.0x 93.5x Lower Multiple TLPH
Revenue Growth (YoY)
Growth
+0.0% -3.3% Higher Growth TLPH
Operating Margin (TTM)
Profitability
-1474700.0% -874.3% Higher Margin BLRX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-143.4% -55.3% Higher ROE BLRX
52-Week Range Position
Momentum
20% ($1–$2) 1% ($1–$4) Stronger Trend TLPH
Beta / 30D Volatility
Risk Regime
1.11β · 58% Vol 0.45β · 68% Vol Lower Realized Risk TLPH
Unified Institutional Score
Composite Signal
37.1 / 100 (SELL) 37.1 / 100 (SELL) Higher Composite Tie
Trailing 12M Revenue (USD)
Operating Scale
$1,000 $1.4M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 80.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 0.20x PEG · 5.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$15M EBITDA ($0.28 Book/Sh · -143.4% ROE) -$12M EBITDA ($3.00 Book/Sh · -55.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TLPH +21.0 pp
TLPH: -20.29% · BLRX: -41.29%
3M Horizon TLPH +29.75 pp
TLPH: -28.85% · BLRX: -58.6%
6M Horizon TLPH +65.76 pp
TLPH: +7.98% · BLRX: -57.78%
1Y Horizon TLPH +47.98 pp
TLPH: -18.01% · BLRX: -65.99%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TLPH vs BLRX. Trailing 12-month operating profitability (TLPH -1474700.0% vs BLRX -874.3%) and valuation multiples (TLPH 1.0x vs BLRX 93.5x Forward P/E) are benchmarked directly in Pillar 4 below.

TLPH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1,000
Gross MarginN/A
Op. Margin-1474700.0%
ROE / Fwd P/E-143.4% · 1.0x
BLRX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.4M
Gross Margin80.0%
Op. Margin-874.3%
ROE / Fwd P/E-55.3% · 93.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TLPH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 118.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TLPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BLRX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 226.3%
IV Percentile 50th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BLRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TLPH Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $53.7M market capitalization and -1474700.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BLRX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $6.9M market capitalization and -874.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ TLPH vs BLRX Key Questions & Quantitative Answers

As of Nov 16, 2026, Talphera, Inc. (TLPH) is the stronger overall head-to-head candidate over BioLineRX Ltd (BLRX) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale). TLPH carries a Unified Composite Score of 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin), whereas BLRX carries 37.1/100 (SELL) at $1.18 (93.5x Forward P/E, -874.3% operating margin). Defensive Composite Rating Caution: Although TLPH compares more favorably head-to-head, both TLPH (37.1/100 SELL) and BLRX (37.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: TLPH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1); meanwhile BLRX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TLPH leads the Growth & Scale pillar: TLPH posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $1,000 TTM revenue (N/A gross margin, -1474700.0% operating margin), compared with BLRX at -3.3% YoY revenue growth and +0.0% YoY earnings growth on $1.4M TTM revenue (80.0% gross margin, -874.3% operating margin). On trailing 12-month operating scale, TLPH generates $1,000 in USD-normalized revenue versus $1.4M for BLRX. In operating R&D and SG&A reinvestment, TLPH deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BLRX.

TLPH screens cheaper on headline valuation multiples. TLPH trades at 1.0x Forward P/E, 1.0x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin), whereas BLRX trades at 93.5x Forward P/E, 93.5x Trailing P/E, 0.20x PEG, and 5.0x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TLPH (-143.4% ROE) versus BLRX (-55.3% ROE) capital efficiency.

In options market volatility and institutional positioning, TLPH carries 118.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.11β · 58% Vol realized risk). By comparison, BLRX carries 226.3% implied volatility (50th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.45β · 68% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.